Thursday, April 16

New Breed of Cancer Vaccine Shows New Promise

Seattle bio-tech company Dendreon has announced that it's anti-cancer vaccine, Provenge, prolongs the lives of prostate cancer patients. 500 patients for who no other therapies were effective participated in the study, but the exact results have not been released (leading to some suspicion regarding the truth of the claim).

While most vaccines rely on prevention, provenge works by targeting immune cells/molecules to established tumors. Many believe this type of vaccine could be less toxic and more effective than chemotherapy or radiation, and when used in conjunction with chemo, the results appear to be synergistic.

However, while preliminary results are certainly promising, the FDA has been reluctant to approve Provenge - inciting outcry and criticism by many cancer-patient advocates. Maybe these latest results will help (when the details are finally released - and if the claims are true).

(link to article about another alt. treatment with nanoparticles)

Image: T-cell

No comments:

Post a Comment